Latest Articles
- ArticleImmunoadsorption therapy in autoimmune encephalitidesMüjgan Dogan Onugoren, Kristin S. Golombeck, Corinna Bien, et al.February 26, 2016
- ArticleThe VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patientsAmandine Mathias, Guillaume Perriard, Mathieu Canales, et al.February 10, 2016
- Clinical/Scientific NotesFailure of alemtuzumab as a rescue in a NMOSD patient treated with rituximabMarkus C. Kowarik, Muna Hoshi, Bernhard Hemmer, et al.February 10, 2016
- ArticleVisual dysfunction, but not retinal thinning, following anti-NMDA receptor encephalitisAlexander U. Brandt, Timm Oberwahrenbrock, Janine Mikolajczak, et al.February 02, 2016
- ArticleSerum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosisImke Metz, Tim Beißbarth, David Ellenberger, et al.February 02, 2016
- Clinical/Scientific NotesDegos disease mimicking primary vasculitis of the CNSSabrina Gmuca, Markus D. Boos, Amanda Treece, et al.February 02, 2016
- ArticlePatients with MS under daclizumab therapy mount normal immune responses to influenza vaccinationYen Chih Lin, Paige Winokur, Andrew Blake, et al.January 27, 2016
- ArticleTherapy with natalizumab is associated with high JCV seroconversion and rising JCV index valuesNicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet, et al.January 27, 2016
- EditorialRising JCV-Ab index during natalizumab therapy for MSInauspicious for a highly efficacious drugAdil Javed, Anthony T. RederJanuary 27, 2016
Pages
Advertisement
Dr. Babak Hooshmand and Dr. David Smith